Van beleggers
voor beleggers
desktop iconMarkt Monitor

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Novacyt PSE:ALNOV.FR, FR0010397232

  • 0,716 20 mei 2024 16:29
  • -0,005 (-0,69%) Dagrange 0,710 - 0,731
  • 57.379 Gem. (3M) 193,4K

Novacyt de volgende biotech raket!

70.386 Posts
Pagina: «« 1 2 3 4 5 6 ... 3520 »» | Laatste | Omlaag ↓
  1. [verwijderd] 2 januari 2018 22:33
    quote:

    Ronny schreef op 2 januari 2018 19:38:

    Weet iemand waar ik goed beeld van dit aandeel kan krijgen. Ben erg geinteresseerd en wil me goed inlezen wat ze doen, welk middel hebben ze al op de markt en wat staat er nog op programma/in planning.

    Dank alvast.
    novacyt.com/

    24/01/2018 2017 annual revenues

    Novacyt Fast 500 PR Paris, France and Cambridge, UK – 2 January 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has been ranked 135 in Deloitte’s Technology Fast 500™ EMEA. The awards rank 500 Technology, Media and Telecommunications companies with the highest rate of growth
  2. [verwijderd] 3 januari 2018 13:19
    This is the region where the growth is happening

    www.businesswire.com/news/home/201709...

    September 04, 2017 01:00 AM Eastern Daylight Time

    PARIS & CAMBRIDGE, England--(BUSINESS WIRE)--Regulatory News:

    Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces it has received its largest single order for Primerdesign’s genesig® q16 instruments. The order, for over 100 instruments has been placed by a single customer based in China.

    As part of the strategic rationale to acquire Primerdesign, Novacyt identified future growth synergies within the business, in particular within the Asia Pacific region. Utilising Novacyt’s existing sales channels, the Company has been able to increase the installed base of instruments in Asia Pacific of Primerdesign’s genesig® q16 instrument. This order represents approximately 50% of the total q16 instruments sold since it was launched in early 2015 and is from a single customer, with payment to be provided ahead of delivery of the instruments.

    Each installed genesig® q16 instrument works exclusively with Novacyt’s menu of approximately 550 genesig® reagents and therefore will also generate recurring revenues from genesig® reagents sales in the future.

    In addition, Novacyt continues to experience strong demand in the Asia Pacific region for its next generation liquid based cytology (LBC) system, NOVAprep®, which further reinforces the Company’s decision to expand its commercial activities across the region. As reported by the Company on 16 August 2017, the first half of 2017 saw NOVAprep® sales increase by 243% to €346,000 compared with H1 2016 and specifically in China, NOVAprep® sales increased from €42,000 in the whole of 2016 to over €270,000 during the first half of 2017. Sales momentum in China and the wider Asia Pacific market continues into the second half of 2017.

    Based on this initial success, Asia Pacific, in particular China, remains a key growth region for Novacyt and further investment in commercial infrastructure is planned during the second half of 2017. For instance, in addition to its current wholly owned subsidiary in China, the Company is evaluating the establishment of another direct sales and marketing subsidiary in a key market of the region and it also continues to evaluate the potential of the Japanese market for its products.
  3. [verwijderd] 11 januari 2018 00:16
    quote:

    wieweet schreef op 17 november 2017 21:47:

    Ach Diede ,jij hebt centen zat. S.D heeft je toch met genoeg centjes uitgekocht?

    lol

    vrgr
    Voor een fooi heeft ie ons uitgekocht.

    En daarna heeft ie me goed genaaid, omdat we dingen alleen mondeling hadden afgesproken.
    Treurig hoe mensen veranderen als het om geld gaat.
  4. [verwijderd] 11 januari 2018 00:20
    quote:

    SJURVM schreef op 8 januari 2018 20:21:

    1.1 million shares traded today much higher than the average of 260K for the last 6 months.

    I wonder if something is finally moving in the right direction for Novacyt?
    All these kind of shares are exploding.
    Don`t understand why Novacyt is that boring.
  5. wieweet 11 januari 2018 08:32
    quote:

    ik ben Diede schreef op 11 januari 2018 00:16:

    [...]
    Voor een fooi heeft ie ons uitgekocht.

    En daarna heeft ie me goed genaaid, omdat we dingen alleen mondeling hadden afgesproken.
    Treurig hoe mensen veranderen als het om geld gaat.
    Zo Diede..duidelijke eerlijke antwoord. Ab.

    Nu gaat hij heerlijk verder met het maandelijks opvijzelen van zijn rendement met "bepaalde"fondsen.

    vrgr
  6. [verwijderd] 18 januari 2018 21:32
    quote:

    Dag_hoor schreef op 13 januari 2018 19:35:

    What is the expectation for this stock the coming months?

    Wat is de verwachting van dit aandeel voor de komende maanden?
    annual revenues presentation on 24/01.
    Price is inching up with resistance 0.79/0.80
    once through next stop is 0.88

    CEO is "keen" to come up with figures so that may be seen as positive.

    If you can park some money for the next 12 months ( and barring any collapse in markets in general)I would aim for €0.98.

    Depending on developments in 12 months time you could see a move to 1.12 or thereabouts.

    Asia is a growth market for Novacyt and in particular China.

    Anyway we'll see.



70.386 Posts
Pagina: «« 1 2 3 4 5 6 ... 3520 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links